ERBB2 and breast carcinoma: Locally advanced (T2–4 or node positive (N+)) human epidermal growth factor receptor 2 (HER2)-positive breast cancer is commonly treated with the neoadjuvant combination of cytotoxic chemotherapy plus dual antibody blockade—Trastuzumab/Pertuzumab (HP) therapy.